Floatz logo

Abt-530

Chronic Hepatitis C

Kirby InstitutePhase 3Dormant
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Chronic Hepatitis C cohort.

Asset / SponsorPhaseRating
Dasabuvir
AbbVie
Phase 3A
PARITAPREVIR
Ain Shams University
Phase 3A
Ribavirin
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Phase 4A
OMBITASVIR
Ain Shams University
Phase 3A
Sofosbuvir
Peking University First Hospital
Phase 4A

View all 50 →

Same molecule, other indications

Abt-530 is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
84 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →